NCT02773030 2026-03-20A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaCelgenePhase 1/2 Active not recruiting466 enrolled 57 charts